Stem cell transplantation in hematological disorders: A developing country experience-impact of cost considerations

Saudi Medical Journal

Volumn 29, Issue 10, 2008, Pages 1484-1489

  El Zimaity, Maha M ^a,b   Hassan, Essam A ^a   El Wahab, Soha E Abd ^a   El Ghaffar, Afaf A Abd ^a   Mahmoud, Nazek A ^a   Elafifi, Amal M ^a   Moussa, Mohamed M ^a   El Gohary, Ghada M ^a   Hagras, Mona M ^a   Mowafy, Nadia M ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NONE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; CYTOMEGALOVIRUS ANTIBODY; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; METHOTREXATE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DEVELOPING COUNTRY; DONOR; DONOR LYMPHOCYTE INFUSION; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EGYPT; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEALTH CARE COST; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; SIDE EFFECT; STEM CELL MOBILIZATION; SURVIVAL RATE; WHOLE BODY RADIATION; ECONOMICS; IMMUNOSUPPRESSIVE TREATMENT; METHODOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; EGYPT; HEALTH CARE COSTS; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 58749095475     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Efiom-Ekaha D. Hematopoietic Stem Cell Transplantation. 2004 (cited on 26 September 2007). Available from: Http://www.emedicine.com
2. Moore T. Bone Marrow Transplantation. 2005 (cited on March 28, 2008). Available from: Http;//www.emedicine.com
3. Braude P, Minger SL, Warwick RM. Stem cell therapy: Hope or hype? BMJ 2005; 330: 1150-1160.
4. Samuel G, Kerridge I, Vowels M, Tricketss A, Chapman J, Dobbins T. Ethnicity, equity and public benefit: A critical evaluation of public umbilical cord blood banking in Australia. Bone Marrow Transplant 2007; 40: 729-734.
5. Wolf D, Reinhard A, Krause U, Seckinger A, Katus H, Kuecherer H, et al. Stem Cell Therapy Improves Myocardial Perfusion and Cardiac Synchronicity: New Application for Echocardiography. J Am Soc Echocardiogr 2007; 20: 512-520.
6. Krause U, Harter C, Seckinger A, Wolf D, Reinhard A, Bea F, et al. Intravenous Delivery of Autologous Mesenchymal Stem Cells Limits Infarct Size and Improves Left Ventricular Function in the Infarcted Porcine Heart. Stem Cells Dev 2007; 16: 31-37.
7. Cova L, Ratti A, Volta M, Fogh I, Cardin V, Corbo M, et al. Stem cell therapy for neurodegenerative diseases: The issue of transdifferentiation. Stem Cells Dev 2004; 13: 121-131.
8. Masson S, Harrison D, Plevris J and Newsome P. Potential of Hematopoietic Stem Cell Therapy in Hepatology: A Critical Review. Stem Cells 2004; 22; 897-907.
9. Yannaki E, Athanasiou E, Xagorari A, Constantinou V, Batis I, Kaloyannidis P, et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol 2005; 33: 108-119.
10. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213-226.
11. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic. Br J Haematol 2004; 125: 613-620.
12. Kantarjian H, Cortes J. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: Using guidelines to make a rational treatment choices. J Natl Compr Canc Netw 2008; Suppl 2: S37-S42.
13. Robin M, Guardiola P, Dombret H, Baruchel A, Esperou H, Ribaud P, et al. Allogeneic bone marrow transplantation for acute myeloblastic leukemia in remission: Risk factors for long-term morbidity and mortality. Bone Marrow Transplant 2003; 31: 877-887.
14. Hamadani M, Awan F, Copelan E. Hamatopoietic Stem Cell Transplant in Adults with Acute Myeloid Leukemia. Biol Blood Marrow Transplant 2008; 14: 556-567.
15. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose Beacopp chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395.
16. Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, et al. Ifosfamide, etoposide, cy-tarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for re-lapsed or refractory lymphomas. Eur J Haematol 2007; 78: 93-101.
17. Abdelkefi A, Ben Othman T, Ladeb S, Torjman L, Ben Abdeladhim A. Rejection of the second allogeneic graft in a child with Fanconi anemia reversed by antilymphocyte globulin and donor lymphocyte infusion. Hematol J. 2003; 4: 452-453.
18. Muñoz Villa D, Díaz de Heredia C, Díaz González MA, Badell Serra I, Martinez Rubio A, González Valentín MA, et al. Severe acquired aplastic anemia: Historical outcome of patients treated by allogeneic bone marrow transplantation from matched sibling donors. A study by the Spanish Group for Bone Marrow Transplantation in Children (GETMON). An Pediatr (Barc) 2008; 69: 5-9.
19. Bean MA, Graham T, Appelbaum FR. Gamma-irradiation of pretransplant blood transfusion from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. Transplantation 1994; 57: 423-426.
20. Pillay D, Webster A, Prentice HG, Griffiths PD. Risk factors for viral reactivation following bone marrow transplantation. Ann Hematol 1992; 64 (Suppl): A148-A151.
21. Angarone M, Ison MG. Prevention and early treatmen of opportunistic viral infections in patients with leukemia and allogeneic stem cell transplantation recipients. J Natl Compr Canc Netw 2008; 6: 191-201.
22. Zekri AR, Mohamed WS, Samra MA, Sherif GM, El-Shehaby AM, El-Sayed MH. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transplant Immunol 2004; 13: 305-311.